secwatch.observer — SEC 8-K summary
======================================

Issuer:     Paysign, Inc. (PAYS)
CIK:        0001496443
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001683168-25-003288
Event type: earnings
Sentiment:  positive
Materiality: 0.80
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Paysign Q1 2025 revenue up 41% to $18.6M, net income $2.59M; raises full-year guidance
--------------------------------------------------------------------------------

- Total revenues $18.60M (+41% YoY); net income $2.59M ($0.05 diluted EPS) vs $309K ($0.01) in Q1 2024.
- Adjusted EBITDA $4.96M (+193.3%); pharma patient affordability revenue surged 260.8% to 46.3% of revenue.
- Added 14 net patient affordability programs (total 90); plasma revenue fell 9.2%, center count 484.
- FY2025 guidance raised: revenue $72-74M, net income $6-7M ($0.10-$0.12 EPS), Adj. EBITDA $16-17M.
- Q2 2025 revenue guided $18.5-19.0M; Gamma acquisition expected to generate $4-5M annual cash cost savings.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1496443/000168316825003288/0001683168-25-003288-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1496443/000168316825003288/paysign_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-25-003288

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer